enVVeno Medical Corporation provided an update on enrollment for its ongoing SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) U.S. pivotal study for the VenoValve and announced two upcoming investor events. The SAVVE pivotal study is a prospective, non-blinded, single arm, multi-center study of 75 CVI patients. To date, the Company has enrolled 57 patients in the study and expects enrollment to be completed before the end of 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5 USD | 0.00% | -1.96% | -2.72% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.72% | 6.66Cr | |
+29.77% | 4.95TCr | |
+1.00% | 4.26TCr | |
+49.51% | 4.25TCr | |
-5.26% | 2.91TCr | |
+13.68% | 2.66TCr | |
-22.99% | 1.86TCr | |
+8.22% | 1.32TCr | |
+32.41% | 1.25TCr | |
+24.01% | 1.21TCr |
- Stock Market
- Equities
- NVNO Stock
- News enVVeno Medical Corporation
- Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study